SBIOALPS Medical Breakthroughs ETF
SBIO Fund Description
SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.
SBIO Factset Analytics Insight
SBIO invests in a concentrated portfolio of biotech companies with drugs in Phase II and Phase III of U.S. Food and Drug Administration (FDA) clinical trials, and limits itself to US-listed firms with market caps between USD 200 million and USD 5 billion. SBIO also screens for sustainability, meaning constituent firms have enough cash on hand to last two years. Given the low historical success rates in clinical trials, the fund is a high-risk, high-reward bet on a small subset of biotech companies. The Underlying Index undergoes semi-annual reconstitution and quarterly rebalance subject to certain caps. The largest stock is capped at 4.5%, and the excess weight is redistributed proportionately over the remainder of the Underlying Index. Prior to July 9, 2019 the fund’s index was Poliwogg Medical Breakthroughs Index, which has the same strategies.
SBIO Summary Data
SBIO Portfolio Data
SBIO Index Data
SBIO Portfolio Management
SBIO Tax Exposures
SBIO Fund Structure
SBIO Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of SBIO. SBIO is rated a 5 out of 5.
SBIO Sector/Industry Breakdown
SBIO Top 10 Holdings[View All]
SBIO Economic Development
SBIO Performance Statistics
SBIO Benchmark Comparison Summary
SBIO Benchmark Comparison Market Cap Size